Idera is advancing to the clinic in autoimmune diseases and certain genetically defined forms of B-cell lymphoma: activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL), Waldenström’s macroglobulinemia and others. Its lead drug candidate, IMO-8400, is designed to modulate immune responses through Toll-like receptors (TLRs).
|January 11, 2017 at 11:00 a.m. PTIdera Pharmaceuticals, Inc. at the J.P. Morgan Healthcare Conference|
|November 16, 2016 at 3:00 p.m. ETIdera Pharmaceuticals, Inc. at Stifel 2016 Healthcare Conference|
|There are currently no events scheduled.|